White House sides with GSK sales reps

Share this article:
Glaxo signage touts firm's drug-testing role in '12 Games
Glaxo signage touts firm's drug-testing role in '12 Games
The U.S. Solicitor General has filed an amicus brief siding with two pharmaceutical sales reps in their overtime case against GlaxoSmithKline.

The lawsuit alleges that the company denied the reps overtime pay by improperly considering them outside salesmen. The term is defined by the Department of Labor, which also has definitions which distinguish between sales and promotional work.

The Solicitor General's brief argues that the plaintiffs fall in the promotional category, because unlike salesmen, they cannot take orders, negotiate prices or determine a patient's best interest – the latter being a physician's job.

The brief concedes that drug reps could be considered salesmen, if only in a colloquial sense, “because they seek to persuade physicians.”

GSK has argued that the sales reps trigger sales, but the Solicitor General's brief says that restrictions surrounding a drug rep's practice make it “impossible to determine with certainty whether a PSR's promotional work induced any particular prescription.”

Novartis settled a similar suit in January, for $99 million, and Schering-Plough was found to owe overtime pay in August.

The Supreme Court is set to hear the sales rep/GSK appeal this spring.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...